{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meeus F"],"funding":["VUB strategic research program","Fund Paul De Knop","Eutopia","Fonds Wetenschappelijk Onderzoek","The Koning Boudewijn Stichting - Fund Catharina Weekers","The Scientific Fund Willy Gepts"],"pagination":["e009110"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11575280"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["Background
Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblastoma cells but not on healthy brain tissue. Nanobody-based (nano)CARs are gaining increasing attention as promising alternatives to classical single-chain variable fragment-based (scFv)CARs, because of their single-domain nature and low immunogenicity. Still, B7-H3 nanoCAR-T cells have not been extensively studied in glioblastoma.Methods
B7-H3 nanoCAR- and scFvCAR-T cells were developed and evaluated in human glioblastoma models. NanoCAR-T cells targeting an irrelevant antigen served as control. T cell activation, cytokine secre"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity."],"pmcid":["PMC11575280"],"funding_grant_id":["OZR3808BOF","G028220N","N/A","2022-J1811380-E003","1SB9724N","40007555","1S61023N","83","50","84","1S68523N","1S05020N"],"pubmed_authors":["Zeven K","Awad RM","Tuyaerts S","Van Riet I","Meeus F","Autaers D","De Vlaeminck Y","Goyvaerts C","Devoogdt N","De Becker A","Neyns B","Funeh CN","Breckpot K"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.","description":"Background
Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of the overexpression of B7-H3 on glioblastoma cells but not on healthy brain tissue. Nanobody-based (nano)CARs are gaining increasing attention as promising alternatives to classical single-chain variable fragment-based (scFv)CARs, because of their single-domain nature and low immunogenicity. Still, B7-H3 nanoCAR-T cells have not been extensively studied in glioblastoma.Methods
B7-H3 nanoCAR- and scFvCAR-T cells were developed and evaluated in human glioblastoma models. NanoCAR-T cells targeting an irrelevant antigen served as control. T cell activation, cytokine secre","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-04T20:38:58.686Z","creation":"2025-04-04T20:38:58.686Z"},"accession":"S-EPMC11575280","cross_references":{"pubmed":["39562005"],"doi":["10.1136/jitc-2024-009110"]}}